Literature DB >> 11493327

Liver steatosis in chronic hepatitis C: a morphological sign suggesting infection with HCV genotype 3.

L Rubbia-Brandt1, G Leandro, L Spahr, E Giostra, R Quadri, P J Malé, F Negro.   

Abstract

AIMS: To identify factors associated with liver steatosis in chronic hepatitis C. METHODS AND
RESULTS: Occurrence and severity of liver steatosis in 254 chronic hepatitis C patients were compared with presence of alcohol abuse, body mass index (BMI) >26, history of intravenous drug addiction and hepatitis C virus (HCV) genotype. Steatosis was found in 109 (43%) patients. The occurrence of steatosis was significantly associated with ongoing alcohol abuse (P=0.03) or HCV genotype 3 (P= 0.003), but not with BMI >26. A moderate to severe steatosis was present in 60% of patients infected with HCV genotype 3, irrespective of the presence of alcohol abuse, BMI >26 or history of intravenous drug addiction. Using a multivariable stepwise logistic regression analysis, infection with genotype 3 had an odds ratio (OR) of 10 (95% confidence interval (CI)=4.56-22) for a liver steatosis, whereas the presence of a cirrhosis at histology had an OR=0.256 (95% CI=0.07-0.92).
CONCLUSIONS: A moderate to severe degree of steatosis of the liver is a morphological sign suggestive of infection with HCV genotype 3, independent of other risk factors of a fatty liver, but it may disappear at late stages of the disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11493327     DOI: 10.1046/j.1365-2559.2001.01208.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  28 in total

1.  Structural analysis of hepatitis C virus core-E1 signal peptide and requirements for cleavage of the genotype 3a signal sequence by signal peptide peptidase.

Authors:  Verena Oehler; Ana Filipe; Roland Montserret; Daniel da Costa; Gaie Brown; François Penin; John McLauchlan
Journal:  J Virol       Date:  2012-05-16       Impact factor: 5.103

Review 2.  Hepatitis C virus and metabolic disorder interactions towards liver damage and atherosclerosis.

Authors:  Umberto Vespasiani-Gentilucci; Paolo Gallo; Antonio De Vincentis; Giovanni Galati; Antonio Picardi
Journal:  World J Gastroenterol       Date:  2014-03-21       Impact factor: 5.742

Review 3.  Nonalcoholic fatty liver disease: a clinical review.

Authors:  David A Sass; Parke Chang; Kapil B Chopra
Journal:  Dig Dis Sci       Date:  2005-01       Impact factor: 3.199

Review 4.  NAFLD/NASH in patients with type 2 diabetes and related treatment options.

Authors:  M G Radaelli; F Martucci; S Perra; S Accornero; G Castoldi; G Lattuada; G Manzoni; G Perseghin
Journal:  J Endocrinol Invest       Date:  2017-11-30       Impact factor: 4.256

Review 5.  Steatosis in chronic hepatitis C: why does it really matter?

Authors:  T Asselah; L Rubbia-Brandt; P Marcellin; F Negro
Journal:  Gut       Date:  2006-01       Impact factor: 23.059

Review 6.  What is expected from the pathologist in the diagnosis of viral hepatitis?

Authors:  Helmut Denk
Journal:  Virchows Arch       Date:  2011-02-26       Impact factor: 4.064

Review 7.  Modulation of host lipid metabolism by hepatitis C virus: Role of new therapies.

Authors:  José A Del Campo; Manuel Romero-Gómez
Journal:  World J Gastroenterol       Date:  2015-10-14       Impact factor: 5.742

Review 8.  Viral hepatitis: new data on hepatitis C infection.

Authors:  Erzsébet Szabó; Gábor Lotz; Csilla Páska; András Kiss; Zsuzsa Schaff
Journal:  Pathol Oncol Res       Date:  2003-12-22       Impact factor: 3.201

Review 9.  Non-alcoholic fatty liver disease: an emerging pathological spectrum.

Authors:  Elie Serge Zafrani
Journal:  Virchows Arch       Date:  2003-12-18       Impact factor: 4.064

10.  Clinicopathological features and genotype distribution in patients with hepatitis C virus chronic liver disease.

Authors:  Rachel Abraham; Banumathi Ramakrishna; Avinash Balekuduru; Hubert Darius J Daniel; Priya Abraham; C Eapen Eapen; George Kurian
Journal:  Indian J Gastroenterol       Date:  2009-08-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.